Decision made at Biohit Oyj's Extraordinary Shareholder Meeting
Biohit Oyj
Company Announcement
23.11.2011 05:25 pm
A decision was made at Biohit Oyj’s Extraordinary Shareholder Meeting on Wednesday 23 November 2011 to approve the agreement between Biohit Oyj and Sartorius Lab Holding GmbH on the sale of Biohit's liquid handling business to Sartorius for EUR 68 million and to authorise the Board of Directors to close the deal. The transaction is subject to approval by the authorities. The deal is expected to be finalised by the end of 2011. The terms of the deal were explained in more detail in a stock exchange release dated 26 October 2011.
All decisions taken at the shareholder meeting were unanimous. The minutes of the meeting will be available to shareholders, no later than two weeks after the meeting, on the company website and at Biohit’s headquarters at Laippatie 1, 00880 Helsinki.
For more information, please contact:
Osmo Suovaniemi
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.com
Distribution:
NASDAQ OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.com
About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is crystallised by its motto “Innovating for Health”. The company assumes social responsibility by producing innovations, new technologies and analysis systems for use in medicine, research institutions and industry. These products help to promote research and diagnostics, while improving quality of life by preventing disease, human suffering and financial loss. Biohit also seeks to innovate and develop the marketing and availability of its products and services, in order to ensure its profitable growth and ability to pay dividends.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations. These can be used to develop safe and cost-effective liquid handling solutions for laboratory work, as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.
Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips, and pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the prevention and early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach.
The Biohit Group employs around 440 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are sold through about 200 distributors in 70 countries.
Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV (www.biohit.com/investors).
Read more at www.biohit.com